载体对Au-Pd双金属催化剂加氢脱硫性能的影响

研究了Al_2O_3,TiO_2-Al_2O_3等载体对Au-Pd双金属催化剂的噻吩加氢脱硫性能的影响,并运用XRD,TPD,BET,TPR等手段对Au-Pd双金属催化剂进行了表征.结果表明,Au-Pd/TiO_2-Al_2O_3催化剂有较好的噻吩加氢脱硫反应活性和稳定性,与Au-Pd/Al_2O_3催化剂相比,Au-Pd/TiO_2-Al_2O_3催化剂有较高的酸密度和酸强度、活性表面积、H_2及CO的吸附量.     

Y2O3 and MgO co-doped ceria based electrolytes

Electrolytes of Ce_1-x-y Y _x Mg _y O_2-0.5x-y were prepared with citrate method and were characterized by inductively coupled plasma-atomic emission spectrometry, energy dispersive spectrometry, powder X-ray diffraction, and impedance spectroscopy. The effect of composition on the structure, conductivity, and stability of the electrolytes were investigated. When 0≤x≤ about 0.2 and 0≤y≤ about 0.05, the electrolytes were all single phase materials of ceria-based solid solution. However, when y> about 0.05, the electrolytes became two-phase materials, Y³⁺ and Mg²⁺ co-doped ceria-based solid solution and free MgO. The sample with nominal composition of Ce_0.815Y_0.065Mg_0.12O_2-d showed ionic conductivity at 973 K close to or even a little higher than that of similarly prepared Ce_0.9Gd_0.1O_1.95, but had lower cost of raw materials and a little better stability in reducing atmosphere. The existing of free MgO improved the stability of the electrolytes in reducing atmosphere, but too much free MgO reduced the conductivity.     

Metabolomic-based investigation of Yinlan alleviating hyperlipidemia by inhibiting blood stasis and phlegm turbidity through the PXR-CYP3A4-ABCB1-FXR pathway

Yinlan lipid regulatory capsule (YL) is a composite traditional Chinese medicine (TCM) new drug to alleviate hyperlipidemia, while its therapeutic mechanism in vivo was not clarified with nontargeted metabolomics investigation. An animal model was established in rats fed a high-fat diet, and their body weights, body mass index (BMI) and blood cholesterol levels were measured. Serum, liver and kidney tissue samples were also extracted for PXR-CYP3A4-ABCB1-FXR signaling pathway research using PCR and UHPLC–MS. The obtained plasma samples were analyzed by UHPLC-Q-TOF-MS metabolomic investigation, which revealed PXR-CYP3A4-related metabolites and changes induced by YL. Finally, the key metabolites were chosen as index components, and their levels in the serum, liver, small intestine and bile were used for simultaneous UHPLC–MS-MS determination. The results indicated that YL was effective in rebalancing blood TG and TC levels (compared to controls). With respect to the PXR-CYP3A4-ABCB1 pathway, as a result of YL’s effect, gene expression or activity of the two targets decreased significantly in both the liver and kidney. The same trend was observed in the serum samples mentioned above. Metabolomics screening and data revealed that 44 metabolites can be regarded as biomarkers related to hyperlipidemia, fatty acids synthesis, and body energy consumption, as well as synthesis, transportation and exertion of cholesterol. YL’s treatment focused on 26 of them, primarily bile acids, indicating that the antihyperlipidemic effect of this drug lies in its inhibitory activity of cholesterol metabolism. Subsequent analysis of those in vivo components revealed that significant increases (compared to the model group) occurred in the blood, liver, small intestine and bile in groups that received medium and high doses of YL (while the low dose was relatively unchanged). Those target components exhibit a close relationship with PXR and/or CYP3A4. The use of YL repressed PXR expression and subsequently decreased CYP3A4 activity. As a result, synthesis of related bile acids increased, while cholesterol levels decreased, consequently leading to the attenuation of hyperlipidemia. This study comprehensively investigated the antihyperlipidemia mechanism of YL based on its repression of PXR-CYP3A4 activity and related metabolite yield, establishing an accurate method for evaluating the therapeutic effect of YL.     

Fe(III)与2,3-二羟基苯磺酸钠配位反应的动力学研究

[H+]在0.01～0.70mol?L-1范围内,离子强度为1.00mol?L-1,[Fe(III)]>>[配体]、[H+]>>[配体]的条件下,研究了Fe(III)与2,3-二羟基苯磺酸钠(Tiron)的配位反应.发现当[H+]≤3.00×10-2mol?L-1时,[Fe(III)]2对反应速率有明显的贡献.求得了相关反应的动力学参数,从而揭示了FeOH2+和FeOH24+与Tiron配位的解离反应途径及FeOH32+的缔合反应机制,并提出了该配位反应的可能机理.     

七-O-乙酰基-β-乳糖异硫氰酸酯的合成、表征及电化学研究

本文合成了并培养出了七-O-乙酰基—β—乳糖异硫氰酸酯的单晶，用X射线衍射分析了其晶体结构。结果表明，晶体为正交晶系，P2₁2₁2₁空间群，a＝1．23282(7)，b＝1．80012(10)，c＝1.85230(10) nm，α＝β＝γ＝90°，V＝4．1107(4) nm³，Z＝4。电化学实验观测到单链DNA和双链DNA对该化合物的峰电流均有明显降低作用，表明化合物与DNA发生了静电作用。     

氧化铬着色的随角异色颜料的制备与性能研究

采用具有干涉色的云母钛作为基质材料,以氧化铬膜着色,制备了随角异色功能颜料。用XRD、X-RiteMA86Ⅱ5角度分光光度计对产物进行测试分析,研究了不同的基质材料对颜料随角异色效果的影响,分析比较了黑白两种不同背底对颜料的明度和变化效果的影响。结果表明,改变基质材料的干涉色可以制得不同变色效果的随角异色颜料,颜料在黑色背底上的明度值变化范围较大,颜料的变色效果比较明显。     

加味异功散对脾虚小白鼠全血Zn、Fe的影响

探讨加味异功能健脾补血的生化机理、对脾虚治疗组、脾虚组和对照组小白鼠全血Zn、Fe含量进行动态观测。结果显示，加味异功散明显提高脾虚治疗组小鼠全血Zn、Fe含量。     

流动注射分光光度法测定微量铜的研究

研究了在ＴｒｉｔｏｎＮ－１０１存在下，２－羟基－３－羧基－５－磺酸基苯重氮氨基偶氮苯（ＨＣＳ－ＤＡＡ）显色流动注射光度测定微量铜的新方法，用ｐＨ０．４～１１．５Ｎａ２Ｂ４Ｏ７－ＮａＯＨ缓冲溶液作载流，ＨＣＳＤＡＡ和ＴｒｉｔｏｎＮ－１０１的混合试剂作试剂流，采双道流路，５３０ｎｍ检测反应生成红色配合物，方法线性范围是０．０２４～０．２０μｇ／ｍＬ，检出限为８ｎｇ／ｍＬ，进样频率为１００样次／ｈ，直接     

固相配位化学反应研究——ⅩⅩⅩⅩⅠ.[Co(NH_3)_5(H_2O)]Br_3,[Cr(NH_3)_5(H_2O)](NO_3)_3与无机盐KY(Y=Cl,Br,Ⅰ)的固相反应动力学研究

本文主要用气相色谱逸出气体分析方法,借助于红外、紫外可见漫反射谱等手段研究了[Co(NH_3)_5(H_2O)]Br_3、[Cr(NH_3)_5(H_2O)](NO_3)_3与无机盐KY(Y=Cl,Br,Ⅰ)的固相反应,计算了失水与失氨的动力学参数,发现第一步反应失水生成一取代中间产物,其活化能与外加阴离子无关,为S_N1过程。第二步失氨反应活化能与中心离子M以及取代基Y有关,当M=Co(Ⅲ)时,反应体系的失氨活化能大小有下列顺序:Cl>Br>Ⅰ(E值分别为187、155、98kJ·mol~(-1)),M=Cr(Ⅲ)时则正好相反:Ⅰ>Br>Cl(E值分别为213、146、79 kJ·mol~(-1))。     

Y2O3:Eu3+纳米线阵列的制备与表征

Y2O3:Eu3+红色荧光粉由于色纯度高、化学性质稳定和量子效率接近100%而广泛用于荧光灯和投影电视等方面.近年来,Y2O3:Eu3+的大量研究工作主要集中于纳米粉末的制备方法及其与体相材料不同的发光特性[1～3].最近,有关Y2O3:Eu3+及其稀土化合物的纳米管、纳米线和纳米带一维材料的制备成为研究热点.Wu Changfeng等[4,5]利用表面活性剂合成了Y2O3 : Eu3+纳米管.激光格位选择激发测试结果表明,Eu3+在纳米管中占据3个不同的格位,其611 nm处的红色发光峰出现了宽化.He Yu等[6]采用水热法及退火处理制备出了Y2O3:Eu3+纳米带,发现Eu3+的发射峰不仅宽化,而且出现了625 nm的新峰.Li Yadong等[7～9]采用水热法制备了稀土氧化物、硫氧化物和氢氧化物等的纳米线和纳米管,并探索了其形成机理,同时发现Y2O3S : yb3+,Er3+具有上转换的性质.